Mechanism of action / Target
PMC-402 is a monoclonal antibody that targets the human TIE2 that regulated activation, proliferation, and repolarization of Tie2 expressing macrophages, resulting in T cell activation. It binds to TIE2 expressing macrophages that activate T cells in the tumor microenvironment (TME).
An increase in T cell activity along with a shift in polarization from M2 to M1 macrophages have been identified in the in an vitro study. PharmAbcine initiated the GLP-tox study of PMC-402 in 1Q21 and expects an IND filing in 3Q22.
* The preclinical data presentation at AACR 2020
2F, Research Building 2, 70,
Yuseong-daero 1689 beon-gil,
Yuseong-gu, Daejeon, 34047, Republic of Korea
R&D Center +82-42-861-2017
Investor Relations +70-4294-6097
COPYRIGHT BY PharmAbcine Inc.
ALL RIGHTS RESERVE